Introduction
============

Cerebral ischemic stroke represents a life threatening neurological disorder that leads to mortality and long-term disability in surviving patients. Ischemic stroke remains one of the main causes of death and disability in the western countries with only very limited therapeutic options ([@B15]).

Acute brain injury after stroke is caused primarily by the lack of oxygen and glucose. In such conditions, mammalian neurons rapidly depolarize, and excessive release of glutamate occurs, causing excitotoxic cell death, largely due to over-activation of glutamatergic *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) receptors. NMDA receptors are highly permeable to Ca^2+^ and are responsible for intracellular Ca^2+^ increase that reaches neurotoxic levels which, by activating cell lipases, endonucleases, proteases, and phosphatases, ultimately bring to acute excitotoxic cell death ([@B10]). Also, one of the early events occurring by an ischemic episode *in vivo* and during oxygen and glucose deprivation (OGD) *in vitro*, is the release of substantial amounts of adenosine ([@B43]; [@B52]; [@B23]).

Adenosine exerts its biological functions via four receptors subtypes, A~1~, A~2A~, A~2B~, and A~3~ ([@B45]). Many studies indicate that A~1~ receptors play a prominent inhibitory tone on synaptic transmission and that adenosine selective antagonists, acting on this receptor subtype, has a protective role under ischemia ([@B57]). Unfortunately, the development of A~1~ receptor selective agonists as possible anti-ischemic drugs has been stalled by their sedative and cardiovascular side effects, including bradycardia and hypotension. Therefore, in order to identify putative targets for therapeutic intervention, the research on possible anti-ischemic drugs has focussed on the contribution of the other adenosine receptors. The role of the adenosine A~2A~ receptor under ischemia has been largely investigated ([@B9]; [@B59]). Among adenosine receptors, the A~2B~ receptor subtype is the least studied and still remains the most enigmatic, because of the relatively low potency of adenosine for this receptor ([@B21]) and the very few selective ligands that have been described so far. Most of the present knowledge on A~2B~ receptors originates from their peripheral role on the control of cardiac myocyte contractility, intestinal tone, asthma, inflammation, cancer and diabetes ([@B19]; [@B34]; [@B8]; [@B53]; [@B2]). A~2B~ receptors play proinflammatory roles in human asthma, in chronic obstructive pulmonary disease and murine colitis ([@B19]; [@B12]; [@B34]). In the central nervous system (CNS), adenosine A~2B~ receptors, although scarcely, are uniformly expressed ([@B16]) including in the hippocampus ([@B60]), but their role or function and in particular under ischemic/hypoxic conditions is still to be clarified. Understanding the processes by which the applications of these compounds confer neuroprotection should shed light on mechanisms to delay or mitigate the pathophysiological effects of ischemic injury.

In this paper we investigated the role of adenosine A~2B~ receptors during OGD in the CA1 region of rat hippocampus, the most susceptible hippocampal area to an ischemic insult. For this purpose two selective adenosine A~2B~ receptor antagonists were used. In order to characterize the OGD-induced cell injury and putative pharmacological protection, we conducted extracellular recordings of CA1 field excitatory post-synaptic potentials (fEPSPs) after a severe (7 min or 30 min) simil-ischemic insult. The response to ischemia consists of complex, concerted actions of the CNS and the peripheral immune system, that is very difficult to reproduce in *in vitro* model. However, these OGD episodes bring about irreversible depression of neurotransmission and the appearance of anoxic depolarization (AD) ([@B23]; [@B63]). AD is a severe neuronal depolarization, which is an early and critical event that has been demonstrated both *in vivo* ([@B67]) and *in vitro* ([@B70]; [@B62]). AD triggers a variety of molecular events, contributes to cell death and represents an unequivocal sign of neuronal injury ([@B67]). The amount of time spent by neurons in AD is an important determinant of neuron fate. Propagation of AD from the ischemic core is one major factor contributing to neuronal death in the area surrounding the ischemic core (the penumbra) ([@B35]). The penumbra constitutes potentially salvageable tissue and hence a pharmacological treatment that delays the onset of AD would help to protect brain tissue from ischemia ([@B29]; [@B67]).

Cell viability, extent of neuronal damage, astrocytes immunoreactivity and activation of apoptosis markers were also assessed by immunohistochemical analysis. Preliminary data were presented at the Society for Neuroscience Meeting ([@B74]).

Materials and Methods {#s1}
=====================

All animal experiments were performed according to the Italian Law on Animal Welfare (DL 26/2014), approved by the Institutional Animal Care and Use Committee of the University of Florence and by the Italian Ministry of Health. All efforts were made to minimize animal sufferings and to use only the number of animals necessary to produce reliable scientific data. Male Wistar rats (Envigo, Italy, 150--200 g body weight) were used. Experiments were carried out on acute rat hippocampal slices, prepared as previously described ([@B62], [@B65]).

Preparation of Slices
---------------------

Animals were killed with a guillotine under anesthesia with isoflurane (Baxter, Rome, Italy) and hippocampi were rapidly removed and placed in ice-cold oxygenated (95% O~2~--5% CO~2~) artificial cerebrospinal fluid (aCSF) of the following composition (mM): NaCl 124, KCl 3.33, KH~2~PO~4~ 1.25, MgSO~4~ 1.4, CaCl~2~ 2.5, NaHCO~3~ 25, and D-glucose 10. Slices (400 μm nominal thickness) were cut using a McIlwain Tissue Chopper (Mickle Laboratory Engineering Co. Ltd., Gomshall, United Kingdom) and kept in oxygenated aCSF for at least 1 h at room temperature. A single slice was then placed on a nylon mesh, completely submerged in a small chamber (0.8 ml) and superfused with oxygenated aCSF (31--32°C) at a constant flow rate of 1.5 ml/min. The treated solutions reached the preparation in 60 s and this delay was taken into account in our calculations.

Extracellular Recordings
------------------------

Test pulses (80 μs, 0.066 Hz) were delivered through a bipolar nichrome electrode positioned in the stratum radiatum of the CA1 region of the hippocampus to stimulate the Schaffer collateral-commissural pathway (**Figure [1A](#F1){ref-type="fig"}**). Evoked potentials were extracellularly recorded with glass microelectrodes (2--10 MΩ, Harvard Apparatus LTD, United Kingdom) filled with 150 mM NaCl. The recording electrode was placed at the dendritic level of the CA1 region to record field excitatory postsynaptic potentials (fEPSPs) (**Figure [1A](#F1){ref-type="fig"}**). Responses were amplified (200×, BM 622, Mangoni, Pisa, Italy), digitized (sample rate, 33.33 kHz), and stored for later analysis with LTP (version 2.30D) program ([@B4]). The amplitude of fEPSP was measured as the difference between the negative peak following the afferent fiber volley and the baseline value preceding the stimulus artifact. In some experiments both the amplitude and the initial slope of fEPSP were quantified, but since no appreciable difference between these two parameters was observed under control conditions, in the presence of drugs or during *in vitro* ischemia, only the measure of the amplitude was expressed in the figures. When a stable baseline of evoked responses was reached, fEPSP amplitudes were routinely measured and expressed as the percentage of the mean value recorded 5 min before the application of any treatment (in particular pre-OGD). Stimulus-response curves were obtained by gradual increase in stimulus strength at the beginning of each experiment. The test stimulus strength was then adjusted to produce a response whose amplitude was 40% of the maximum and was kept constant throughout the experiment. Simultaneously, with fEPSP amplitude, AD was recorded as negative extracellular direct current (d.c.) shifts induced by OGD. The d.c. potential is an extracellular recording considered to provide an index of the polarization of cells surrounding the tip of the glass electrode ([@B18]). AD latency, expressed in min, was calculated from the beginning of OGD; AD amplitude, expressed in mV, was calculated at the maximal negativity peak. In the text and bar graphs, AD amplitude values were expressed as positive values. The terms "irreversible synaptic failure" or "irreversible loss of synaptic transmission" used in the present work refer to the maximal time window of cell viability in our experimental model (acutely isolated hippocampal slice preparation) which, according to our previous results is 24 h ([@B65]).

![Experimental methods. **(A)** Microphotography of an hippocampal slice showing the three subregions, the localization of the stimulating and recording electrodes and the region of interest (ROI, framed area) for the immunohistochemical analyses. SP, stratum pyramidale; SR, stratum radiatum. Scale bar: 200 μm. **(B)** Schematic representation of the experimental method.](fphar-09-00399-g001){#F1}

### Paired-Pulse Facilitation

To elicit paired-pulse facilitation (PPF) of fEPSP, we stimulated the Schaffer collateral-commissural fibers twice with a 40-ms interpulse interval. Double stimulation was evoked once every 15 s. The synaptic facilitation was quantified as the ratio (P2/P1) between the slope of the fEPSP elicited by the second (P2) and the first (P1) stimuli. PPF was monitored in control conditions for at least 5 min before the application of BAY606583. The effect of BAY606583 on PPF was evaluated by measuring the P2/P1 ratio during at least 5 min after 15 min of agonist application.

Drugs
-----

Two selective adenosine A~2B~ receptors antagonists, N-(4-Cyanophenyl)-2-\[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dip-ropyl-1H-purin-8-yl)phenoxy\]-acetamide) (MRS1754) and 8-\[4-\[4-(4-Chlorophenzyl) piperazide-1-sulfonyl) phenyl\]\]-1-propyl xanthine (PSB603) were used. D-2-amino-5-phosphonovalerate, a selective NMDA receptor antagonist was used. All these compounds were purchased from Tocris (Bristol, United Kingdom). The A~1~ receptor antagonist DPCPX (8-cyclopentyl-1,3-dipropylxanthine) was purchased from SIGMA Aldrich (<https://www.sigmaaldrich.com>).

All drugs were dissolved in dimethyl sulphoxide (DMSO). Stock solutions, of 1000--10,000 times the desired final concentration, were stored at -20°C. The final concentration of DMSO (0.05% and 0.1% in aCSF) used in our experiments did not affect either fEPSP amplitude or the depression of synaptic potentials induced by OGD (data not shown).

Application of OGD and Adenosine A~2B~ Receptor Antagonists
-----------------------------------------------------------

The experimental method is shown in **Figure [1B](#F1){ref-type="fig"}**. Conditions of OGD were obtained by superfusing the slice with aCSF without glucose and gassed with nitrogen (95% N~2~--5% CO~2~) ([@B58]). This causes a drop in pO~2~ in the recording chamber from ∼500 mmHg (normoxia) to a range of 35--75 mmHg (after 7 min OGD) ([@B64]). At the end of the ischemic period, the slice was again superfused with normal, glucose-containing, oxygenated aCSF. The terms 'OGD slices' or 'treated OGD slices' refer to hippocampal slices in which OGD was applied in the absence or in the presence of A~2B~ receptor antagonists, respectively. Control slices were not subjected to OGD or treatment with A~2B~ receptor antagonists but were incubated in oxygenated aCSF for identical time intervals. All the selective adenosine A~2B~ receptors antagonists were applied 15 min before, during and 5 min after OGD. In a typical experimental day, first a control slice was subjected to 7 min of OGD. If the recovery of fEPSP amplitude after 60 min of reperfusion with glucose containing and normally oxygenated aCSF was ≤15% of the pre-OGD value, and AD developed into 7 min OGD, a second slice from the same rat was subjected to an OGD insult in the presence of the A~2B~ receptor antagonist under investigation. To confirm the result obtained in the treated group, a third slice was taken from the same rat and another 7 min OGD was performed under control conditions to verify that no difference between slices was caused by the time gap between the experiments. In some slices the OGD period was prolonged to 30 min and the A~2B~ receptor antagonists were applied 15 min before and during OGD application. After the extracellular recordings, slices were maintained in separate chambers for 1 or 3 h from the end of OGD in oxygenated aCSF at room temperature (RT). At the end, slices were harvested and fixed overnight at 4°C in 4% paraformaldehyde in PBS, cryopreserved in 18% sucrose for 48 h, and resliced as written below.

Treatment of Hippocampal Slices With Glutamate *in Vitro*
---------------------------------------------------------

Experiments were carried out on acute hippocampal slices, prepared from male Wistar rats as described above. The A~2B~ receptor antagonists were dissolved in DMSO to obtain a stock solution suitable for a 1:2000 dilution. Slices, maintained oxygenated throughout the procedure, were incubated according to the following scheme:

1.  Control slices were incubated for 1 h in aCSF and then for 25 min in aCSF with DMSO (1:2000; 0.05%);

2.  Glutamate (GLU) treated slices were incubated 1 h in aCSF and then for 10 min with 100 μM glutamate in aCSF;

3.  MRS+GLU treated slices were incubated for 1 h in aCSF, then for 15 min with 500 nM MRS1754 and for further 10 min with 500 nM MRS1754 plus 100 μM glutamate, in aCSF;

4.  PSB+GLU treated slices were incubated for 1 h in aCSF, then for 15 min with 50 nM PSB603, and for further 15 min with 50 nM PSB603 plus 100 μM glutamate in aCSF;

After the incubation with glutamate and A~2B~ receptor antagonists, slices were further incubated for 3 h in aCSF, and then harvested and fixed overnight at 4°C in 4% paraformaldehyde in PBS, cryopreserved in 18% sucrose for 48 h, and resliced as written below.

Immunohistochemistry
--------------------

One hour or 3 h after OGD, or after the incubation with glutamate and A~2B~ receptor antagonists, the 400 μm thick slices fixed in paraformaldehyde were placed on an agar support (6% agar in normal saline), included in an embedding matrix and re-sliced with a cryostat to obtain 40 μm thick slices. The more superficial sections were eliminated, while those obtained from the inner part of the slice were collected and stored in vials with 1 ml of antifreeze solution at -20°C until immunohistochemical analyses. From the 400 μm thick slices on average only a maximum of 2--3 complete 40 μm thick slices were obtained, which were then randomly allocated to the fluorescent immunohistochemical staining groups.

### Antibodies Used -- Primary Antibodies

Neurons were immunostained with a mouse monoclonal anti-NeuN antibody (1:200, MilliporeSigma, Carlsbad, CA, United States), astrocytes were detected by means of a polyclonal rabbit antibody anti-Glial Fibrillary Acidic Protein (GFAP, 1:500, DakoCytomation, Glostrup, Denmark), Cytochrome C with a mouse monoclonal antibody (1:200, Abcam, Cambridge, United Kingdom). Activated mTOR was detected using a polyclonal rabbit primary antibody raised against phospho-(Ser2448)-mTOR (1:100, Abcam, Cambridge, United Kingdom). Fluorescent secondary antibodies: Alexa Fluor 488 donkey anti rabbit (fluorescence in green, 1:400), Alexa Fluor 555 donkey anti mouse (fluorescence in red, 1:400), Alexa Fluor 635 goat anti-rabbit (fluorescence in far red, 1:400) (all from Life Technologies, Carlsbad, CA, United States). All primary and secondary antibodies were dissolved in Blocking Buffer (BB, 10% Normal Goat Serum, 0.05% NaN~3~ in PBS-TX). All procedures were carried out with the free-floating method in wells of a 24-well plate ([@B7]; [@B37]).

### Day 1

The sections were washed (3 times, 5 min each) in PBS-0.3% Triton X-100 (PBS-TX), blocked with 500 μl BB for 1 h, at RT under slight agitation and then incubated overnight at 4°C with the primary antibody under slight agitation.

### Day 2

After washing in PBS-TX (3 times, 5 min each), sections were incubated for 2 h at room temperature in the dark with a solution containing one or two (for double immunostaining) fluorescent secondary antibodies, as appropriate. Sections were washed (3 times, 5 min each) with BB and then with 1 ml of distilled H~2~O at RT in the dark, mounted on gelatinized microscopy slides, dried and coverslipped with a mounting medium containing DAPI to counterstain nuclei (Vectashield, Hard set mounting medium with DAPI, Vector Laboratories, Burlingame, CA, United States). Sections were kept refrigerated in the dark until microscopy analyses.

### Day 3

Qualitative and quantitative analyses of NeuN positive neurons, CytC and phospho-mTOR positive cell bodies were performed in CA1 stratum pyramidale (SP), while astrocytes, phospho-mTOR positive dendrites and microglia were performed in CA1 stratum radiatum (SR) as shown in **Figure [1A](#F1){ref-type="fig"}**. Epifluorescence microscopy: sections were observed under an Olympus BX63 microscope equipped with an Olympus DP 50 digital camera (Olympus, Milan, Italy). For quantitative analysis images were acquired at 20× magnification with the digital camera.

### Confocal Microscopy

Scans were taken at 0.3 μm z-step, keeping constant all the parameters (pinhole, contrast, and brightness), using a LEICA TCS SP5 confocal laser scanning microscope (Leica Microsystems CMS GmbH, Mannheim, Germany). Images were converted to green, or red using ImageJ (freeware provided by National Institute of Health^[1](#fn01){ref-type="fn"}^). The region of interest (ROI) in CA1, containing stratum pyramidalis and stratum radiatum was consistently analyzed in all slices, as shown in **Figure [1A](#F1){ref-type="fig"}** ([@B39]). Quantitative analyses of NeuN^+^ neurons, HDN neurons, LDN neurons, GFAP^+^ astrocytes, CytC^+^ apoptotic neurons and phospho-mTOR positive cell bodies and dendrites were performed blind by two experimenters and results were averaged. Areas were expresses as mm^2^. Digitized images were transformed into TIFF files and thresholded using ImageJ. Care was taken to maintain the same threshold in all sections within the same experiment. In CA1 pyramidal layer, the area labeled above the set threshold with NeuN or phospho-mTOR was calculated in pixels and expressed as NeuN^+^ pixels/mm^2^ or phospho-mTOR^+^ pixels/mm^2^. HDN neurons, LDN neurons, Cytochrome C-positive (CytC^+^) apoptotic neurons in CA1 stratum pyramidale and GFAP^+^ astrocytes in CA1 stratum radiatum were counted and were expressed as number of cells/mm^2^. In order to evaluate mTOR activation in basal dendrites the length of phospho-mTOR^+^ dendrites was measured at three fixed locations, equal in all slices and evenly distributed throughout the CA1 stratum radiatum ROI, and results were averaged.

Statistical Analysis
--------------------

Statistical significance was evaluated by Student's paired or unpaired *t-*tests. Analysis of variance (one-way ANOVA), followed by Newman--Keuls multiple comparison *post hoc* test was used, as appropriate. *P*-values from both Student's paired and unpaired *t*-tests are two-tailed. Data were analyzed using software package GraphPad Prism (version 7.0; GraphPad Software, San Diego, CA, United States). All numerical data are expressed as the mean ± standard error of the mean (SEM). A value of *P* \< 0.05 was considered significant.

Results
=======

Electrophysiological Experiments
--------------------------------

It has been established that 7 min OGD episodes bring about irreversible depression of neurotransmission and the appearance of a severe neuronal depolarization or AD ([@B62], [@B63], [@B65]), a critical event that has been demonstrated both *in vivo* ([@B67]) and *in vitro* ([@B20]; [@B56]; [@B62], [@B63], [@B65]; [@B23]). Therefore, we studied the effects of two selective adenosine A~2B~ receptor antagonists, MRS1754 and PSB603, on AD development in the CA1 region of acute rat hippocampal slices under severe OGD episodes by extracellular recording of fEPSPs on 133 hippocampal slices taken from 42 rats.

The Selective Adenosine A~2B~ Receptor Antagonism Prevents or Delays AD Development and Protects From Synaptic Failure Induced by Severe OGD in CA1 Hippocampus
---------------------------------------------------------------------------------------------------------------------------------------------------------------

In agreement with our previous results ([@B62], [@B63], [@B65]), in untreated OGD slices the d.c. shift presented a mean latency of 6.04 ± 0.2 min (calculated from the beginning of OGD) and a mean peak amplitude of -6.7 ± 0.4 mV (*n* = 24) (**Figure [2A](#F2){ref-type="fig"}**). Seven min OGD exposure induced a rapid and irreversible depression of fEPSPs amplitude evoked by Schaffer-collateral stimulation, since synaptic potentials did not recover their amplitude after return to oxygenated aCSF (**Figure [2D](#F2){ref-type="fig"}**, *n* = 24, 2.5 ± 2.7% of pre-OGD level, calculated 50 min from the end of OGD). Control slices, followed for up to 3 h in oxygenated aCSF, maintained stable fEPSPs for the entire experimental time recording and never developed the d.c. shift (data not shown).

![The selective adenosine A~2B~ receptor antagonists MRS1754 or PSB603 significantly reduced the synaptic failure induced by 7 min oxygen and glucose deprivation (OGD) in the CA1 region of rat hippocampal slices. **(A--C)** anoxic depolarization (AD) was recorded as a negative direct current (d.c.) shift in response to 7 min OGD in untreated OGD slices **(A)**, in 500 nM MRS1754-treated slices **(B),** or 50 nM PSB603-treated slices **(C)**. Note that MRS1754 prevented the appearance of AD in 13 out of 17 slices, while PSB603 in 11 out of 15 slices. **(D)** The graph shows the time-course of the effect of 7 min OGD on field excitatory post-synaptic potential (fEPSP) amplitude, expressed as percentage of pre-OGD baseline in the CA1 hippocampal region in the absence (*n* = 24) or in the presence of 500 nM MRS1754 (*n* = 17). Note that, in untreated slices, the ischemic-like insult caused gradual reduction, up to disappearance, of fEPSPs amplitude that did not recover after washing in oxygenated artificial cerebrospinal fluid (aCSF). On the contrary, after reperfusion in oxygenated standard solution, a recovery of fEPSP in all MRS1754 treated OGD slices was found, even in those in which AD developed. **(E)** The graph shows the time course of the effect of 7 min OGD on fEPSP amplitude in 50 nM PSB603 treated OGD slices. Note that, after reperfusion in normal oxygenated standard solution, a recovery of fEPSP was found in all OGD-treated PSB603 slices, even those in which AD occurred. **(F, Left)** each column represents the mean ± SEM of AD latency recorded in the CA1 region during 7 min OGD in the absence or in the presence of MRS1754 (500 nM) or PSB603 (50 nM). AD latency was measured from the beginning of OGD insult. Note that when OGD was applied in the presence of MRS1754 or PSB603 the appearance of AD was significantly delayed in comparison to OGD untreated slices. ^∗^*P* \< 0.05 vs. OGD, One-way ANOVA followed by Newman--Keuls Multiple comparison test. **(Right)** each column represents the mean ± SEM of AD amplitude recorded in the CA1 during 7 min OGD. The number of slices is reported in the columns. **(G)** The graph shows the time course of the effect of 7 min OGD on fEPSP amplitude in OGD-untreated slices and in 500 nM MRS1754- or 50 nM PSB603-treated slices. The selective antagonism of adenosine A~2B~ receptors counteracted the CA1 synaptic damage induced by severe OGD up to 3 h from the end of the insult. Inset: 7 min OGD induced AD was recorded untreated OGD slices, but not in the presence of 500 nM MRS1754 or 50 nM PSB603. Gray bar: OGD time duration. Open bar: time of drug application. Amplitude of fEPSPs (mean ± SEM) is expressed as percentage of pre-OGD baseline.](fphar-09-00399-g002){#F2}

Oxygen and glucose deprivation was then applied in the presence of the selective adenosine A~2B~ receptor antagonists MRS1754 or PSB603, administered 15 min before, during and 5 min after OGD.

The two A~2B~ receptor antagonists did not modify basal synaptic transmission measured before OGD. Indeed, MRS1754 (500 nM, *n* = 17) did not modify fEPSPs amplitude under normoxic conditions (from 1.05 ± 0.06 mV immediately before to 1.01 ± 0.08 mV after 15 min drug application, *n* = 17). Also, PSB603 did not change the amplitude of synaptic potentials under normoxic conditions (from 1.32 ± 0.12 mV before to 1.35 ± 0.14 mV after 15 min drug application, *n* = 15). These data indicate that the blockade of A~2B~ receptors does not modify low-frequency-induced CA1 synaptic transmission under normoxic conditions, in agreement with results reported in mouse hippocampal slices ([@B26]).

Nevertheless, the two A~2B~ receptor antagonists were able to prevent or delay the appearance of AD and to modify synaptic responses after OGD.

During 7 min OGD, MRS1754 prevented the appearance of AD in 13 out of 17 slices tested (**Figure [2B](#F2){ref-type="fig"}**). In these 13 slices a complete recovery of fEPSPs was recorded (111.9 ± 7.4%, calculated 50 min from the end of OGD, **Figure [2D](#F2){ref-type="fig"}**). In the remaining 4 slices, AD developed, although at later times (**Figure [2F](#F2){ref-type="fig"}**, mean AD latency: 7.37 ± 0.41 min; mean peak amplitude: -5.8 ± 1.1 mV, *n* = 4), and, unexpectedly, was followed by a consistent fEPSP recovery (85.2 ± 15.3%, *n* = 4, **Figure [2D](#F2){ref-type="fig"}**).

During 7 min OGD, PSB603 prevented the appearance of AD in 11 out of 15 slices tested (**Figure [2C](#F2){ref-type="fig"}**). In these 11 slices a complete recovery of fEPSPs was found (110.4 ± 10.2%, *n* = 11, **Figure [2E](#F2){ref-type="fig"}**). In the remaining four slices in which AD appeared, a delay in AD latency was recorded (**Figure [2F](#F2){ref-type="fig"}**, mean AD latency: 7.33 ± 0.08 min; mean peak amplitude: -6.8 ± 1.9 mV, *n* = 4). Moreover, in these four PSB603-treated slices, a significant recovery of fEPSP (36.2 ± 19.7%, *n* = 4, **Figure [2E](#F2){ref-type="fig"}**) was found.

In the slices in which AD appeared in the presence of MRS1754 or PSB603, we compared the time of AD appearance in the absence and in the presence of drugs. As illustrated in **Figure [2F](#F2){ref-type="fig"}**, during 7 min OGD, AD appeared in OGD slices with a mean latency of 6.04 ± 0.2 min (Left panel) and a mean peak amplitude of 6.7 ± 0.4 mV (*n* = 24, Right panel). When 7 min OGD was applied in the presence of 500 nM MRS1754 or 50 nM PSB603 the d.c. shifts were always delayed (**Figure [2F](#F2){ref-type="fig"}**, Left panel), while AD amplitude values were not significantly modified in comparison to OGD slices (**Figure [2F](#F2){ref-type="fig"}**, Right panel).

In an experimental group of slices which never developed AD in the presence of PSB603 (50 nM) (*n* = 6) and MRS1754 (500 nM) (*n* = 6), we followed the evolution of the synaptic response for 3 h after the end of the 7 min ischemic like insult in comparison to untreated OGD slices (*n* = 6). As reported in the representative electrophysiological traces shown in **Figure [2G](#F2){ref-type="fig"}**, PSB603 (50 nM) and MRS1754 (500 nM) allowed the recovery of synaptic potentials for at least 3 h after 7 min OGD.

Furthermore, in order to confirm that both the recovery of fEPSP and the irreversible loss of neurotransmission after 7 min OGD observed in the different experimental groups were not transient, we tested slice viability 24 h after the OGD insult in control, untreated, slices and slices treated with A~2B~-receptor antagonists. In agreement with our previously published results ([@B65]), we showed that untreated OGD slices, which did not recover any synaptic activity within 1 h after the insult, maintained synaptic impairment when tested 24 h later (Supplementary Figure [1A](#SM3){ref-type="supplementary-material"} shows a representative experiment out of a total of six slices). On the contrary, MRS1754- or PSB603-treated OGD slices, which recovered initial fEPSP amplitude 1 h after OGD, preserved neurotransmission for at least 24 h after the insult (Supplementary Figure [1B](#SM3){ref-type="supplementary-material"} shows a representative experiment out of a total of four slices, and Supplementary Figure [1C](#SM3){ref-type="supplementary-material"} shows a representative experiment out of a total of five slices for MRS1754 and PSB603, respectively).

In order to characterize the role of adenosine A~2B~ receptors on AD development, in a next series of experiments we prolonged the OGD duration up to 30 min, in order to allow AD to unavoidably appear in all experimental groups. This longer duration of OGD is invariably associated with tissue damage ([@B56]). We compared the latency and the magnitude of depolarizing d.c. shifts recorded in the absence or presence of PSB603 or MRS1754. As illustrated in **Figure [3A](#F3){ref-type="fig"}**, 30 min OGD elicited the appearance of AD in all slices, with a mean peak amplitude of -7.5 ± 0.7 mV (*n* = 8) and a mean latency of 5.8 ± 0.3 min, as shown in **Figures [3D,E](#F3){ref-type="fig"}**. When OGD was applied in the presence of 500 nM MRS1754, the d.c. shift was significantly delayed to 9.2 ± 0.7 min (**Figures [3B, D](#F3){ref-type="fig"}**; *n* = 5), although the AD amplitude (-5.7 ± 0.7 mV) was not significantly changed (**Figure [3E](#F3){ref-type="fig"}**). Similarly, when OGD was applied in the presence of 50 nM PSB603, the d.c. shift was significantly delayed to 7.7 ± 0.3 min (**Figures [3C,D](#F3){ref-type="fig"}**; *n* = 7) whereas AD amplitude (-7.7 ± 0.7 mV) was unchanged (**Figure [3E](#F3){ref-type="fig"}**).

![MRS1754 and PSB603 delayed the appearance of AD induced by 30 min OGD in rat hippocampal slices. **(A--C)** The graphs show the d.c. shift traces during 30 min OGD in untreated OGD slices (**A**, *n* = 8), in the presence of 500 nM MRS1754 (**B**, *n* = 5), or 50 nM PSB603 (**C**, *n* = 7). **(D)** Each column represents the mean ± SEM of AD latency recorded in hippocampal slices during 30 min OGD in different experimental groups. AD was measured from the beginning of OGD insult. Note that both adenosine A~2B~ receptor antagonists significantly delayed AD development. ^∗∗^*P* \< 0.01 vs. OGD, One-way ANOVA followed by Newman--Keuls Multiple comparison test. **(E)** Each column represents the mean ± SEM of AD amplitude recorded in the CA1 during 30 min OGD. The number of slices is reported in the columns.](fphar-09-00399-g003){#F3}

Data in the literature demonstrate that adenosine A~2B~ receptors exert their effects through a control of A~1~ receptor function in the hippocampus under simil-physiological, normoxic, conditions ([@B26]). In order to test this possibility, we studied whether A~2B~ receptor antagonists were still effective in inhibiting OGD-induced alterations of synaptic transmission in the presence of the A~1~ receptor antagonist DPCPX. As shown in Supplementary Figures [2A--C](#SM4){ref-type="supplementary-material"}, we applied DPCPX before, during and after a 7 min OGD and, unexpectedly, we found that 2 out of 6 slices tested did not undergo AD and completely recovered their synaptic activity. This unexpected result was possibly due to the unselective block of A~2A~ receptors by DPCPX, as already described in hippocampal slices during OGD ([@B68]). Therefore, we reduced DPCPX concentration to 100 nM and we prolonged the OGD period up to 30 min (Supplementary Figure [2D](#SM4){ref-type="supplementary-material"}). Under these experimental conditions, DPCPX-exposed slices presented a delayed AD appearance (mean AD peak time = 8.4 ± 0.5 min) in comparison to control, untreated, OGD slices (mean AD peak time = 6.8 ± 0.2 min) thus confirming that DPCPX protects hippocampal slices from OGD insults (Supplementary Figure [2E](#SM4){ref-type="supplementary-material"}). The time window of A~2B~ or A~1~ receptor-mediated effects found in the present studies overlaps with the delay found treating the slices with glutamate receptor antagonists ([@B70]; [@B76]), or blocking NMDA receptors that are involved both in initiation and propagation of AD ([@B27]; [@B67]). In a further series of experiments, we demonstrated that D-AP5 (50 μM) significantly delayed AD appearance (from 6.8 ± 0.2 min in untreated OGD slices to 9.8 ± 1.0 min in D-AP5-treated OGD slices, Supplementary Figure [2E](#SM4){ref-type="supplementary-material"}).

For this reason, in order to assess the involvement of A~1~ receptors in A~2B~ receptor-mediated effects, we choose a different protocol. It has been shown that short-term plasticity, measured by PPF, is modified by A~2B~ receptor activation in mouse hippocampal slices in a DPCPX-sensitive manner ([@B26]). We confirmed that the A~2B~ receptor agonist BAY606583, at 200 nM concentration, significantly decreased PPF in rat CA1 hippocampus (**Figure [4](#F4){ref-type="fig"}**), thus indicating an increase of presynaptic glutamate release upon A~2B~ receptor activation. This effect was blocked not only by the A~2B~ receptor antagonists PSB603 and MRS1754, but also by the A~1~ receptor antagonist DPCPX (**Figure [4B](#F4){ref-type="fig"}**), thus confirming that A~2B~ receptor effects are mediated by the inhibition of the A~1~ subtype, as already stated by [@B26].

![The selective stimulation of adenosine A~2B~ receptors reduced paired-pulse facilitation (PPF) in rat hippocampal slices. **(A)** Trace of fEPSP responses to PPF protocol (40-ms interval), taken from a typical experiment. Calibration: 0.5 mV, 20 ms. **(B)** Each graph shows PPF quantified as the ratio (P2/P1) between the slope of the second fEPSP (P2) and the slope first fEPSP (P1). The effect of BAY606583 (BAY, 200 nM) on PPF was investigated in the absence (*n* = 7) or in the presence of MRS1754 (500 nM, *n* = 3), PSB603 (50 nM, *n* = 3), or DPCPX (100 nM, *n* = 7). ^∗^*P* \< 0.05 vs. ctr, paired Student's *t*-test.](fphar-09-00399-g004){#F4}

Analysis of Neuronal Damage in CA1 Stratum Pyramidale 1 and 3 h After the End of 7 min OGD
------------------------------------------------------------------------------------------

The extent of neuronal damage caused by 7 min OGD in stratum pyramidale of hippocampal CA1 was assessed by immunohistochemistry using the anti-NeuN antibody in control slices, in slices after 7 min OGD alone, and after 7 min OGD in the presence of 500 nM MRS1754 or 50 nM PSB603, both at 1 and 3 h after the end of OGD. Representative images of NeuN immunostaining in CA1 of slices collected 1 h after the end of OGD are shown in **Figures [5A](#F5){ref-type="fig"}--[D](#F5){ref-type="fig"}**.

![Analysis of NeuN^+^ immunofluorescence in CA1 stratum pyramidale after the simil-ischemic insult. **(A--D)** Representative images of NeuN^+^ immunofluorescence in the ROI of CA1 of a control slice (CTR, **A**), a slice collected 1 h after 7 min OGD (OGD, **B**), a slice treated with 500 nM MRS1754 (OGD+MRS, **C**), and a slice treated with 50 nM PSB603 (OGD+PSB, **D**), all harvested 1 h after the end of 7 min OGD. Scale bar: 75 μm. **(E,F)** Quantitative analyses of NeuN^+^ immunofluorescence in the four experimental groups 1 h **(E)** and 3 h **(F)** after the end of 7 min OGD. Each column represents the area, expressed in pixels (×10^6^) above a threshold, maintained constant for all slices investigated. **(E)** Statistical analysis: One-way ANOVA: *F*~(3;13)~ = 6.296, *P* \< 0.01, Newman--Keuls multiple comparison test: ^∗^*P* \< 0.05, OGD vs. CTR; ^\$^*P* \< 0.05, OGD+PSB vs. OGD. CTR, *n* = 6; OGD, *n* = 5; OGD+PSB, *n* = 3; OGD+MRS, *n* = 3. **(F)** Statistical analysis: One-way ANOVA: *F*~(3,16)~ = 4.924, *P* \< 0.02; Newman--Keuls multiple comparison test: ^∗^*P* \< 0.05 OGD vs. CTR, ^\#^*P* \< 0.05 OGD+MRS vs. OGD,^\$^*P* \< 0.05 OGD+PSB vs. OGD. CTR, *n* = 6; OGD, *n* = 3; OGD+PSB, *n* = 4; OGD+MRS *n* = 4. All data in the graphs are expressed as mean ± SEM.](fphar-09-00399-g005){#F5}

**Figures [5E,F](#F5){ref-type="fig"}** show the quantitative analyses of the area of NeuN^+^ immunofluorescence in CA1, which represents an index of the number of pyramidal neurons, 1 and 3 h after the end of OGD, respectively. The data demonstrate that NeuN^+^ CA1 pyramidal neurons significantly decreased both 1 h (**Figure [5E](#F5){ref-type="fig"}**) and 3 h (**Figure [5F](#F5){ref-type="fig"}**) after the end of 7 min OGD. Statistical analysis showed that 7 min OGD caused a statistically significant reduction of NeuN^+^ area at 1 h (-29.6%, ^∗^*P* \< 0.05 vs. control slices) and at 3 h (-41%, ^∗^*P* \< 0.05 vs. control slices). The time-course of the effect, indicating that the decrease of NeuN^+^ area was more pronounced at 3 h than at 1 h after the end of OGD, demonstrates that neuronal degeneration is an ongoing process at least at these time points.

The decrease of NeuN^+^ area in CA1 stratum pyramidale was completely antagonized by treatment with 50 nM PSB603 (-1% at 1 h and -14% at 3 h, ns vs. control slices). This effect was statistically significant vs. 7 min OGD slices both at 1 and 3 h after the end of OGD (^\$^*P* \< 0.05 vs. respective OGD). Treatment with 500 nM MRS1754 completely blocked the decrease of NeuN^+^ area in CA1 stratum pyramidale 3 h after the end of OGD (-7% vs. control slices, ns; ^\#^*P* \< 0.05 vs. OGD). MRS1754 had no effect 1 h after the end of OGD (-31.5% vs. control slices; ns vs. OGD). Therefore, antagonism of A~2B~ receptors blocked the neuronal damage induced by 7 min OGD up to 3 h after the end of the simil-ischemic insult. In the OGD slices treated either with MRS1754 or PSB603 that developed AD we found a partial reduction of neuronal damage at 1 h after the end of OGD (data not shown).

Closer examination of CA1 stratum pyramidale with confocal microscopy indicated the presence of many damaged neurons both 1 and 3 h after the end of 7 min OGD. The representative confocal z stacks in **Figures [5B](#F5){ref-type="fig"}**, **[6B](#F6){ref-type="fig"}**, each obtained stacking 37 consecutive confocal z-scans (0.3 μm each, total thickness 11.1 μm) through the thickness of CA1, show that 3 h after the end of OGD the layout and morphology of CA1 pyramidal neurons was significantly different from that of the control slice (**Figure [6A](#F6){ref-type="fig"}**). **Figures [6A1,B1](#F6){ref-type="fig"}** are magnification of the framed areas in **Figures [6A,B](#F6){ref-type="fig"}**, and show stacks of two consecutive z-scans, 0.3 μm each, total thickness 0.6 μm, taken at 2.1 μm depth inside the neurons. It appears evident from panel **Figure [6B1](#F6){ref-type="fig"}** the altered morphology of pyramidal neurons after OGD, in comparison to those of the control slice shown in **Figure [6A1](#F6){ref-type="fig"}**. Indeed, in CA1 stratum pyramidale of OGD slices, both at 1 and 3 h after the end of OGD, we observed the presence of many neurons with nuclei that exhibit a highly condensed NeuN-positive nucleus and very faint NeuN cytoplasmic labeling (**Figures [6B,B1](#F6){ref-type="fig"}**, open arrows). We defined these neurons as High Density Nucleus neurons, "HDN neurons." Furthermore, we observed many NeuN^+^ neurons that have lost the NeuN^+^ nuclear immunofluorescence, an index of damaged nuclei, while NeuN^+^ immunofluorescence persists in the cytoplasm (**Figures [6B,B1](#F6){ref-type="fig"}**, white arrows). We defined these neurons as Low Density Nucleus neurons, "LDN neurons."

![Analysis of damaged neurons in CA1 stratum pyramidale after the simil-ischemic insult. **(A--B1)** Representative images of NeuN^+^ immunofluorescence in the CA1 area of a control slice (CTR, **A,A1**), and of a slice harvested 3 h after the end of 7 min OGD (OGD, **B,B1**). **(A1--B1)** magnification of digital subslices of the framed areas in **A,B** (stacks of two consecutive z-scans taken at 2.1 μm depth inside the neurons, total thickness 0.6 μm). Note the presence of many HDN neurons (open arrows) and LDN neurons (white arrows) in CA1 stratum pyramidale after OGD **(B,B1)**. Scale bars: **A,B**: 25 μm; **A1,B1**: 10 μm. **(C,D)** Quantitative analyses of NeuN^+^ HDN neurons in CA1 stratum pyramidale 1 h **(C)** and 3 h **(D)** after the end of OGD. **(C)** One-way ANOVA: *F*~(3;12)~ = 11.32, *P* \< 0.001. Newman--Keuls multiple comparison test: ^∗∗^*P* \< 0.01, OGD vs. CTR; ^\#\#^*P* \< 0.01, OGD+MRS vs. CTR;^\$\$\$^*P* \< 0.001 OGD+PSB vs. OGD. CTR, *n* = 5; OGD, *n* = 5; OGD+PSB, *n* = 3; OGD+MRS, *n* = 3. **(D)** One-way ANOVA: *F*~(3;12)~ = 64.33, *P* \< 0.001. Newman--Keuls multiple comparison test: ^∗∗∗^*P* \< 0.001, OGD vs. CTR; ^\#\#\#^*P* \< 0.001, OGD+MRS vs. OGD;^\$\$\$^*P* \< 0.001 OGD+PSB vs. OGD. CTR, *n* = 5; OGD, *n* = 3; OGD+PSB, *n* = 4; OGD+MRS, *n* = 4. **(E--F)**: Quantitative analysis of NeuN^+^ LDN neurons in CA1 stratum pyramidale 1 h **(E)** and 3 h **(F)** after the end of OGD. **(E)** One-way ANOVA: *F*~(3;14)~ = 13.80, *P* \< 0.001. Newman--Keuls multiple comparison test: ^∗∗∗^*P* \< 0.01, OGD vs. CTR; ^\#\#^*P* \< 0.01, OGD+MRS vs. CTR;^\$\$\$^*P* \< 0.001 OGD+PSB vs. OGD. CTR, *n* = 6; OGD, *n* = 6; OGD+PSB, *n* = 3; OGD+MRS, *n* = 3. **(F)** One-way ANOVA: *F*~(3;12)~ = 69.77, *P* \< 0.001. Newman--Keuls multiple comparison test: ^∗∗∗^*P* \< 0.001, OGD vs. CTR; ^\#\#\#^*P* \< 0.001, OGD+MRS vs. OGD;^\$\$\$^*P* \< 0.001 OGD+PSB vs. OGD. CTR, *n* = 5; OGD, *n* = 3; OGD+PSB, *n* = 4; OGD+MRS, *n* = 4. All data in the graphs are expressed as mean ± SEM.](fphar-09-00399-g006){#F6}

In order to better characterize this phenomenon, we performed the quantitative analysis of HDN and LDN neurons in control, 7 min OGD, 7 min OGD plus MRS1754 and 7 min OGD plus PSB603 slices at 1 and 3 h after the end of OGD. The results, presented in **Figures [6C,D](#F6){ref-type="fig"}**, show that HDN neurons increased significantly in 7 min OGD slices both at 1 h (+603% vs. control slices, ^∗∗^*P* \< 0.01) and 3 h (+794% vs. control slices, ^∗∗∗^*P* \< 0.001) after the end of OGD. The increase of damaged, HDN neurons in the CA1 area caused by the simil-ischemic insult was significantly blocked by treatment with 50 nM PSB603 at 1 and 3 h after the end of OGD (-97% at 1 h, and -77% at 3 h vs. 7 min OGD slices, both ^\$\$\$^*P* \< 0.001; ns vs. controls). Conversely, treatment with 500 nM MRS1754 significantly blocked the increase of HDN neurons only 3 h after the end of OGD (-70% vs. 7 min OGD slices, ^\#\#\#^*P* \< 0.001; ns vs. control slices), but not 1 h after the end of OGD (+12% vs. OGD slices, ns; ^\#\#^ *P* \< 0.01 vs. control slices).

Also, as shown by the representative images in **Figures [6B,B1](#F6){ref-type="fig"}**, we found many LDN neurons in stratum pyramidale 1 and 3 h after the end of 7 min OGD. As demonstrated by quantitative analysis (**Figures [6E,F](#F6){ref-type="fig"}**) LDN neurons in stratum pyramidale were significantly increased both 1 and 3 h after OGD, in comparison to control slices. The increase of LDN neurons, in comparison to control slices, was 1489% at 1 h (^∗∗∗^*P* \< 0.01 vs. control slices) and 1033% at 3 h after the end of 7 min OGD (^∗∗∗^*P* \< 0.01 vs. control slices). The increase of damaged, LDN neurons brought about by the simil-ischemic insult was significantly blocked by treatment with 50 nM PSB603 both at 1 and 3 h after the end of OGD (-98% at 1 h, and -62% at 3 h vs. OGD, both ^\$\$\$^*P* \< 0.001). Treatment with 500 nM MRS1754 significantly blocked the increase of LDN neurons only 3 h after the end of OGD (-52% vs. 7 min OGD,^\#\#\#^*P* \< 0.001), but not 1 h after the end of OGD (-17% vs. 7 min OGD, ns; ^\#\#^*P* \< 0.01 vs. controls). These data further confirm the efficacy of the two A~2B~ receptor antagonists, and particularly of PSB603, in reducing not only the electrophysiological effects but also the morphological modifications that OGD caused on CA1 pyramidal neurons, up to 3 h after the end of the ischemic-like insult.

Analysis of Apoptotic Neurons in Stratum Pyramidale of CA1 1 and 3 h After 7 min OGD
------------------------------------------------------------------------------------

These data demonstrate that 7 min OGD can induce neuronal damage in CA1 stratum pyramidale, as evidenced by immunohistochemical analyses that highlight conformational modifications of pyramidal neurons that may subtend cell death. Therefore, we studied whether all the above-described effects and the decrease of neurons in CA1 stratum pyramidale might be caused by apoptosis. To this end, as an apoptosis marker we used CytC, a protein which, in physiological conditions, is found in mitochondria but in the most advanced stages of apoptosis is intensely and diffusely released in the cytoplasm, where it activates caspases ([@B33]; [@B77]; [@B30]; [@B69]) and can be used as a marker of apoptosis using immunohistochemical analysis ([@B51]). Using a selective antibody, CytC can be visualized in apoptotic cells as an intense and diffuse cytoplasmic immunostaining, as shown by the white arrows in the representative confocal images of an OGD slice 1 h after the end of OGD (**Figures [7A--A2](#F7){ref-type="fig"}**). As shown in the confocal subslice of the framed area of **Figure [7A2](#F7){ref-type="fig"}**, obtained stacking 17 consecutive confocal z-scans through the CytC^+^ neuron (0.3 μm each, total thickness 5.1 μm), it is evident that the CytC^+^ positive neuron is a LDN neuron (**Figures [7B--B2](#F7){ref-type="fig"}**, open arrow), thus demonstrating that LDN neurons are apoptotic.

![Analysis of CytocromeC^+^ (CytC^+^) neurons in CA1 stratum pyramidale after the simil-ischemic insult. **(A--A2)** Representative microphotographs, taken at the laser scanning confocal microscope, of apoptotic neurons labeled with anti-CytC antibody (**A**, red), of pyramidal neurons labeled with anti-NeuN antibody (**A1**, green) and the merge of the two previous images **(A2)**. NeuN^+^ and CytC^+^ apoptotic neurons in CA1 stratum pyramidale are indicated by the arrows (yellow-orange color in **A2**). Scale bar: 25 μm. **(B--B2)** Subslice of the framed area in **A2**, obtained stacking 17 consecutive confocal z-scans (5.1 μm total thickness), shown at higher magnification (2×). The open arrow shows an LDN apoptotic pyramidal neuron. Scale bar: 10 μm. **(C,D)** Quantitative analysis of NeuN^+^ and CytC^+^ neurons in CA1 stratum pyramidale at 1 h **(C)** and 3 h **(D)** after the end of 7 min OGD. Note the significant increase of CytC^+^ neurons both 1 and 3 h after the end of OGD. **(C)** Statistical analysis: One-way ANOVA: *F*~(3;11)~ = 18.40, *P* \< 0.001, Newman--Keuls multiple comparison test: ^∗∗∗^*P* \< 0.001, OGD vs. CTR; ^\#\#\#^*P* \< 0.001, OGD+MRS vs. OGD; ^\$\$\$^*P* \< 0.001, OGD+PSB vs. OGD. CTR, *n* = 4; OGD, *n* = 3; OGD+PSB, *n* = 4; OGD+MRS, *n* = 4. **(D)** Statistical analysis: One-way ANOVA: *F*~(3;11)~ = 11.41, *P* \< 0.02, Newman--Keuls multiple comparison test: ^∗∗^*P* \< 0.01, OGD vs. CTR; ^\#^*P* \< 0.05, OGD+MRS vs. OGD; ^\$\$^*P* \< 0.01, OGD+PSB vs. OGD. CTR, *n* = 4; OGD, *n* = 3; OGD+PSB, *n* = 4; OGD+MRS, *n* = 4. All data in the graphs are expressed as mean ± SEM.](fphar-09-00399-g007){#F7}

From the quantitative analysis of CytC^+^ neurons in CA1 stratum pyramidale, we demonstrated that both 1 and 3 h after the end of 7 min OGD many CA1 pyramidal neurons were apoptotic (**Figures [7C,D](#F7){ref-type="fig"}**). The increase was statistically significant in comparison to control slices both at 1 h (+277% vs. control slices, ^∗∗∗^*P* \< 0.001) and at 3 h (+107% vs. control slices, ^∗∗^*P* \< 0.01) after OGD. These data indicate that in CA1 area, already after 1 h from the end of OGD, neurons had clear signs of apoptotic processes. In the presence of MRS1754 or PSB603, there was a significant reduction of CytC immunostaining, both at 1 and 3 h after the end of OGD, showing that antagonism of A~2B~ receptors significantly reduced neuronal death by apoptosis at both times investigated. Indeed, treatment with MRS1754 decreased apoptotic neurons by 61% at 1 h (^\#\#\#^*P* \< 0.001 vs. 7 min OGD; ns vs. control slices) and by 33% at 3 h (^\#^*P* \< 0.05 vs. 7 min OGD; ns vs. control slices), in comparison to OGD slices. Treatment with PSB603 decreased apoptotic neurons by 63% (^\$\$\$^*P* \< 0.001 vs. 7 min OGD; ns vs. control slices) and by 46% (^\$\$^*P* \< 0.001 vs. 7 min OGD; ns vs. control slices) in comparison to OGD slices. In the OGD slices treated either with MRS1754 or PSB603 that developed AD the number of HDN and LDN neurons were partially decreased in comparison to OGD slices (data not shown).

These data indicate that in the CA1 area already 1 h after the end of OGD, when there was still no recovery of neurotransmission, neurons showed obvious signs of apoptosis. These data demonstrate that antagonism of A~2B~ receptors brought about significant protection against neuron degeneration.

Analysis of Phospho-mTOR in Area CA1 of the Hippocampus 1 and 3 h After 7 min OGD
---------------------------------------------------------------------------------

We used a selective antibody for phospho-(Ser244)-mTOR, the activated form of mTOR, to investigate whether mTOR activation might be modified in our experimental conditions (**Figures [8A--D1](#F8){ref-type="fig"}**). Representative qualitative images of mTOR activation in cell bodies and dendrites of CA1 pyramidal neurons in a control slice are shown in **Figure [8A1](#F8){ref-type="fig"}** (green). Neurons were also immunolabelled with anti-NeuN antibody (red). The merge of the immunofluorescence (yellow-orange) in a control slice is shown in **Figure [8A](#F8){ref-type="fig"}**. It is evident from the images that activated mTOR is present in CA1 pyramidal neurons in basal, control conditions where it is localized both in the cell body and in neuronal apical dendritic tree spanning throughout the stratum radiatum. The simil-ischemic condition caused a significant decrease of mTOR activation 3 h after the end of OGD, as shown in the representative image of **Figures [8B,B1](#F8){ref-type="fig"}**. This effect is more evident in **Figures [8E,F](#F8){ref-type="fig"}**, that represent digital subslices obtained stacking nine consecutive confocal z-scans throughout the neuronal cell bodies (0.3 μm each, total thickness 2.7 μm) of control and OGD slices. The images clearly show that in control conditions phospho-mTOR was present both in the cell body (**Figure [8E](#F8){ref-type="fig"}**, open arrow) and in the dendrites (**Figure [8E](#F8){ref-type="fig"}**, white arrows), while 3 h after 7 min OGD activation of mTOR decreased both in cell body and dendrites (**Figure [8F](#F8){ref-type="fig"}**). Quantitative analysis showed that in slices harvested 1 h after the end of 7 min OGD, no significant modification of activated mTOR immunostaining was present in the neuronal cell body (**Figure [8G](#F8){ref-type="fig"}**) or in the apical dendrites of CA1 pyramidal neurons in any of the groups investigated (**Figure [8I](#F8){ref-type="fig"}**). On the contrary, in slices harvested 3 h after the end of 7 min OGD, we found highly significant decrease of activated mTOR immunostaining in the cytoplasm and dendrites of CA1 pyramidal neurons (**Figures [8H,J](#F8){ref-type="fig"}**). Indeed, statistical analysis, shown in **Figure [8H](#F8){ref-type="fig"}**, demonstrates that 3 h after the end of 7 min OGD there was a statistically significant reduction of activated mTOR immunostaining in the cytoplasm of CA1 pyramidal neurons (-74.8%, ^∗∗∗^*P* \< 0.001 vs. control slices, **Figure [8H](#F8){ref-type="fig"}**) in comparison to control slices. As shown in **Figure [8H](#F8){ref-type="fig"}**, treatment with 50 nM PSB603 blocked this effect (-4% vs. control slices, ns, ^\$\$\$^*P* \< 0.001 vs. 7 min OGD), while treatment with 500 nM MRS1754 partially, but still significantly attenuated this effect (-31% vs. controls, ns, ^\#\#^*P* \< 0.01 vs. 7 min OGD).

![mTOR activation in CA1 stratum pyramidale and stratum radiatum after the simil-ischemic insult. Representative microphotographs, taken at the laser scanning confocal microscope, showing immunolabelling with anti-NeuN antibody (red) and anti-phospho-mTOR antibody (green) of a control slice **(A,A1)**, a slice harvested 3 h after 7 min OGD **(B,B1)**, a slice treated with MRS1754 and harvested 3 h after 7 min OGD **(C,C1)**, and a slice treated with PSB603 and harvested 3 h after 7 min OGD **(D,D1)**. Scale bar: 75 μm. **(E,F)** Digital subslices of a control slice **(E)** and a slice collected 3 h after 7 min OGD **(F)** immunostained for phospho-mTOR (green) and NeuN (red). The open arrow shows the presence of activated mTOR in the cell body and arrows in the dendrites of pyramidal neurons in the control slice **(E)**. **(G,H)** Quantitative analysis of activated mTOR in CA1 stratum pyramidale in the different experimental conditions. Each column represents the mTOR^+^ immunofluorescent area calculated using the ImageJ program (number of pixels above a reference, fixed threshold). **(G)** No difference among the four experimental groups, was found 1 h after the end of 7 min OGD. Statistical analysis: One-way ANOVA: *F*~(3;11)~ = 0.4563, *P* \> 0.05, ns. **(H)** Slices harvested 3 h after the end of 7 min OGD. Note the significant decrease of activated mTOR in CA1 pyramidal neurons 3 h after the end of OGD. Both MRS1754 and PSB603 significantly blocked this effect. Statistical analysis: One-way ANOVA: *F*~(3;10)~ = 26.99, *P* \< 0.001, Newman--Keuls multiple comparison test: ^∗∗∗^*P* \< 0.001, OGD vs. CTR; ^\#\#^*P* \< 0.01, OGD+MRS vs. OGD; ^\$\$\$^*P* \< 0.001, OGD +PSB vs. OGD. CTR, *n* = 4; OGD, *n* = 3; OGD+PSB, *n* = 3; OGD+MRS, *n* = 4. All data are expressed as mean ± SEM. **(I,J)** Quantitative analysis of phospho-mTOR^+^ dendrites in CA1 stratum radiatum in the different experimental conditions. **(I)** Length of phospho-mTOR^+^ dendrites in CA1 stratum radiatum 1 h after the end of 7 min OGD. No difference among the four experimental groups was observed. Statistical analysis: One-way ANOVA: *F*~(3;11)~ = 0.7143, *P* \> 0.05, ns. **(J)** Length of mTOR^+^ dendrites in CA1 stratum radiatum 3 h after the end of 7 min OGD. Note the significant decrease of activated mTOR in dendrites 3 h after the end of OGD. PSB603 significantly blocked this effect. Statistical analysis: One-way ANOVA: *F*~(3;9)~ = 12.38, *P* \< 0.02, Newman--Keuls multiple comparison test: ^∗∗^*P* \< 0.01, OGD vs. CTR; ^\$^*P* \< 0.05, OGD+PSB vs. OGD. CTR, *n* = 3; OGD, *n* = 3; OGD+PSB, *n* = 3; OGD+MRS, *n* = 4. All data in the graphs are expressed as mean ± SEM.](fphar-09-00399-g008){#F8}

We used, as a determinant of mTOR activation in the dendrites, the analysis of the length of phospho-mTOR positive dendrites, as reported in the methods. The results shown in **Figure [8I](#F8){ref-type="fig"}** reveal that mTOR activation was not statistically significant among the four experimental groups 1 h after the end of 7 min OGD. However, in the slices collected 3 h after the end of 7 min OGD we found a significant decrease of mTOR positive dendrites in the stratum radiatum of the CA1 area (**Figure [8J](#F8){ref-type="fig"}**). From the statistical analysis we demonstrated a significant decrease of mTOR immunopositive dendrites in CA1 stratum radiatum of 7 min OGD slices 3 h after the end of OGD (-80% vs. controls, ^∗∗^*P* \< 0.01, **Figure [8J](#F8){ref-type="fig"}**). The selective antagonist MRS1754, did not significantly modify this effect, while treatment with PSB603 partially, but significantly, reversed this effect (+226% vs. 7 min OGD,^\$^*P* \< 0.05). These data demonstrate that OGD significantly decreased mTOR activation and that the selective antagonism selective antagonism of A~2B~ receptors significantly reduced this impairment, a further indication of prevention of neuronal degeneration by blockade of this receptor.

Analysis of Astrocytes in CA1 Stratum Radiatum After 7 min OGD
--------------------------------------------------------------

Astrocytes were labeled with the anti-GFAP antibody and quantified in the stratum radiatum of CA1 hippocampus in the four experimental conditions: in control slices, in slices after 7 min OGD alone, and after 7 min OGD in the presence of 500 nM MRS1754 or 50 nM PSB603, both at 1 and 3 h after the end of OGD, as shown in the representative microphotographs in **Figures [9A](#F9){ref-type="fig"}--[D](#F9){ref-type="fig"}**, taken at 3 h after the end of OGD.

![Quantitative analysis of astrocytes in the CA1 area in the different experimental conditions after the simil-ischemic insult. **(A--D)** Representative microphotographs, taken at the epifluorescence microscope, of astrocytes immunolabelled with anti-GFAP antibodies in the stratum radiatum (green) of a control **(A)**, OGD **(B)**, OGD plus MRS1754 **(C)**, and OGD plus PSB603 **(D)** slice. Scale bar: 50 μm. **(E,F)** Quantitative analysis of astrocytes in the stratum radiatum of CA1 in control, OGD, OGD plus MRS1754, and OGD plus PSB603 slices at 1 h **(E)** and 3 h **(F)** after 7 min OGD. **(E)** No significant differences among the four experimental groups analyzed was found. Statistical analysis: One-way ANOVA: *F*~(3;18)~ = 0.877, *P* \> 0.05, ns. CTR, *n* = 8; OGD, *n* = 7; OGD+PSB, *n* = 3; OGD+MRS, *n* = 4. **(F)** Statistical analysis: One-way ANOVA: *F*~(3;15)~ = 6.734, *P* \< 0.01, Newman--Keuls multiple comparison test: ^∗∗^*P* \< 0.01, OGD vs. CTR; ^\$^*P* \< 0.05, OGD+PSB vs. OGD. CTR, *n* = 7; OGD, *n* = 4; OGD+PSB, *n* = 4; OGD+MRS, *n* = 4. All data in the graphs are expressed as mean ± SEM.](fphar-09-00399-g009){#F9}

In the stratum radiatum of slices harvested 1 h after the end of 7 min OGD we found a slight, not significant increase of astrocytes (**Figure [9E](#F9){ref-type="fig"}**, +19%, ns vs. controls), which became significant at 3 h after the end of 7 min OGD (**Figure [9F](#F9){ref-type="fig"}**, +43% vs. control slices, ^∗∗^*P* \< 0.01). Both A~2B~ receptor antagonists, partially but significantly, reduced the increase of astrocytes caused by the simil-ischemic conditions. MRS1754 decreased the number of astrocytes by 10% (ns vs. OGD), while PSB603 by 13% (^\$^*P* \< 0.05 vs. OGD).

Quantitative analysis of total microglia did not reveal statistically significant modifications in the different experimental conditions both at 1 and 3 h after the end of 7 min OGD (data not shown).

Neurodegeneration of CA1 Pyramidal Neurons Induced by Glutamate Was Not Prevented by Adenosine A~2B~ Receptor Antagonists
-------------------------------------------------------------------------------------------------------------------------

In order to have an insight into the mechanism of A~2B~ receptor antagonism-induced neuroprotection, we verified whether MRS1754 and PSB603 might protect CA1 pyramidal neurons from the well-known neurodegenerative effects caused by glutamate exposure. We incubated the hippocampal slices *in vitro* with 100 μM glutamate for 10 min and verified the effect of MRS1754 and PSB603 on glutamate-induced cell death (**Figures [10A](#F10){ref-type="fig"}--[D](#F10){ref-type="fig"}**).

![Evaluation of glutamate induced neurotoxicity in CA1 stratum pyramidale in the different experimental conditions. **(A--C)** Representative microphotographs, taken at the epifluorescence microscope, of CA1 pyramidal neurons immunolabelled with anti-NeuN antibodies in a control slice **(A)**, a slice treated with glutamate (GLU, **B**), a slice treated with glutamate plus PSB603 (GLU+ PSB, **C**) slice. Scale bar: 50 μm. **(D)** Quantitative analyses of NeuN^+^ HDN neurons in the four experimental groups 3 h after the end of drug incubation. Statistical analysis: One-way ANOVA: *F*~(3;15)~ = 3.313, *P* \< 0.05, Newman--Keuls multiple comparison test: ^∗^*P* \< 0.05, vs. all other groups. CTR, *n* = 6; GLU, *n* = 6; GLU+PSB, *n* = 3; GLU+MRS, *n* = 4.](fphar-09-00399-g010){#F10}

Administration of 100 μM glutamate for 10 min caused significant damage to pyramidal neurons at 3 h after the end of incubation, evidenced by the significant increase of HDN neurons in hippocampal CA1, as shown in the representative image presented in **Figure [10B](#F10){ref-type="fig"}**. Quantitative analysis (**Figure [10D](#F10){ref-type="fig"}**) demonstrated that the increase of HDN neurons was statistically significant in comparison to control slices, and that neither MRS1754 nor PSB603 protected CA1 pyramidal neurons from the excitotoxic effect of glutamate (^∗^*P* \< 0.05 vs. all other groups).

Discussion
==========

The putative protective role of adenosine A~2B~ receptors in cerebral ischemia was studied in the CA1 region of hippocampal slices under oxygen-glucose deprivation, an experimental condition that mimics, albeit with the limits of *in vitro* methodology, the most common causes of cerebral ischemia, such as vessel occlusion. *In vitro* slices give a partial view of the physiology of the brain because of the absence of an intact vascular system and the altered tridimensional microenvironment. These alterations involve not only neurons but also glia, and more generally the physiology of the neurovascular unit formed by astrocytes, pericytes, microglia, neurons, and the extracellular matrix ([@B28]). Nevertheless, the *in vitro* systems have many benefits such as the opportunity to obtain highly valuable information in terms of the time-course of the electrophysiological events, changes in membrane potential (AD), changes in synaptic transmission and morphological and biochemical changes in neurons and glia. Our results confirm that in the CA1 region of rat hippocampus, the application of a 7 min OGD episode induced the appearance of AD which was followed by irreversible synaptic damage and neurodegeneration of CA1 pyramidal neurons ([@B64], [@B62], [@B65]; [@B11]; [@B72]). We now demonstrate that these events are accompanied by neurodegeneration of CA1 pyramidal neurons, with reduction of neuronal density and significant increase of apoptotic neurons. For the first time we demonstrated here that antagonism of A~2B~ receptors using the selective ligands MRS1754 or PSB603, applied before, during and after OGD, prevented or delayed the appearance of AD, and prevented the irreversible loss of neurotransmission induced by 7 min OGD. Furthermore, we demonstrated that the selective blockade of A~2B~ receptors during a prolonged (30 min) OGD insult delays the appearance of AD indicating an extension of the time window between the start of the insult and the appearance of excitotoxic damage. Adenosine A~2B~ receptor antagonism also counteracted the reduction of neuronal density in CA1 stratum pyramidale and decreased apoptosis mechanisms at least up to 3 h after the end of the insult. Both A~2B~ receptor antagonists did not protect CA1 neurons from neurodegeneration induced by glutamate application, indicating that the antagonistic effect is upstream of glutamate release.

The hippocampus, and particularly CA1 stratum pyramidale, is one of the most vulnerable brain regions to ischemic damage. We used the acute rat hippocampal slice preparation which allows measurements of synaptic transmission with good spatial and temporal resolution. In the early phases, hypoxia/ischemia is known to induce a massive increase of extracellular glutamate levels which trigger hyperactivation of glutamate receptors, production of reactive oxygen species, pathological increase of intracellular Ca^2+^, rapid decrease in ATP reserves and activation of various proteolytic enzymes ([@B32]; [@B3]; [@B36]). In hippocampal slices, a severe OGD insult as that applied in the present experiments (7 min) elicits the appearance of AD within the OGD period and is invariably followed by irreversible loss of neurotransmission ([@B23]; [@B63], [@B65]), an index of cell suffering, damage to neurons and to the surrounding tissue ([@B67]). AD is caused by the sudden increase of extracellular K^+^ and by the contemporary explosive rise in glutamate extracellular concentration ([@B67]). Contemporarily to the extracellular increase of glutamate, the extracellular concentration of adenosine significantly increases, as demonstrated both in *in vivo* and *in vitro* experiments ([@B45]). After 5 min OGD, adenosine reaches an extracellular concentration of 30 μM in hippocampal slices ([@B44]; [@B56]). At such high concentration adenosine can stimulate all receptor subtypes, including the A~2B~ receptor, which exhibits affinity for adenosine with an EC~50~ in the range of 5--20 μM, lower than all other subtypes ([@B21]). For this reason, it is possible that activation of A~2B~ receptors occurs mainly during pathological conditions, such as inflammation, hypoxia, trauma, and ischemia ([@B22]).

Our data show that A~2B~ receptor antagonists, by preventing or delaying the onset of AD, prevent the irreversible loss of neurotransmission induced by 7 min OGD allowing complete recovery of synaptic potentials. We showed for the first time a partial recovery of neurotransmission was also observed in a group of hippocampal slices, treated with A~2B~ receptor antagonists, that developed AD immediately after reoxygenation. This delay of AD appearance might account for the partial recovery of neurotransmission observed in these slices. The occurrence of AD after the end of OGD period is a peculiar characteristic that we observed in our hippocampal preparation. We envisage that when the AD appears during the reoxygenation period, similarly to the phenomenon of spreading depression ([@B67]), neurons are less damaged, and they can partially recover their electrical activity. Thus, even in those slices treated with the A~2B~ receptor antagonists in which AD takes place, this event is less harmful to neuronal viability. This is a substantial difference from A~2A~ receptor antagonist-mediated neuroprotection during a 7 min OGD insult. Indeed, fEPSP recovery was never observed in those few slices undergoing AD in the presence of the A~2A~ receptor blocker ZM241385, as previously published ([@B65]).

As to the mechanism by which A~2B~ receptor antagonists protect from hypoxia/ischemia, recent studies by [@B26] have demonstrated that in mouse hippocampus A~2B~ receptors are expressed on glutamatergic terminals anatomically comparable to those from which our recordings were performed. Their selective stimulation counteracts the predominant A~1~ receptor-mediated inhibition of synaptic transmission. We confirmed this assumption by performing PPF experiments in rat hippocampal slices in which the A~2B~ receptor agonist BAY606583 was able to reduce PPF ratio, which is known to be caused by increased glutamate release at presynaptic level. This effect is counteracted not only by the A~2B~ receptor antagonists MRS1754 and PSB603 but also by the A~1~ receptor antagonist DPCPX. As already hypothesized ([@B54]; [@B26]), this result may be related to the existence of an A~1~/A~2B~ receptor heterodimer in the CA1 hippocampal region. On these bases, our purpose was to study the possible involvement of A~1~ receptors in the neuroprotective effects elicited by the two A~2B~ receptor antagonists during OGD. In accordance to data reported by [@B6] in a model of chemical penumbra produced by a mitochondrial gliotoxin in the hippocampus *in vitro*, we would have expected conservation of synaptic transmission during the first min of OGD and acceleration of AD appearance. In our conditions, a similar response was observed only in a limited number of slices during 7 min OGD. Instead, in most of the slices we demonstrated that DPCPX induced neuroprotection during OGD, delaying AD appearance. This unexpected result may be due to a different response of A~1~ receptors during OGD in our experimental conditions. Our data could also be explained considering the results obtained by [@B68] who demonstrated that DPCPX decreases glutamate release from hippocampal slices subjected to OGD and that this effect is mimicked and occluded by the A~2A~ receptor antagonist ZM241385. The same Authors hypothesize that DPCPX, even at low nanomolar concentrations, would directly bind to A~2A~ receptors during severe ischemia (in accordance with our previously published results, [@B65]). The rational for this assumption is that the A~2A~ receptor agonist CGS21680 displays two distinct binding sites in the hippocampus: a "typical" (striatal-like) binding site which is displayed by DPCPX only at high (submicromolar) concentrations, and an "atypical" binding site, which shows high affinity for DPCPX ([@B31]; [@B13]). On these bases, we can hypothesize that, in our OGD experiments, DPCPX binds to this "atypical" binding site (i.e., an A~1~--A~2A~ receptor heterodimer) thus decreasing glutamate outflow and protecting hippocampal slices from OGD insults. Furthermore, when overstimulated such as during ischemia, A~1~ receptors undergo desensitization ([@B66]). This phenomenon can be further increased by A~2B~ receptors activation, triggering a vicious circle in which the beneficial effect of A~1~ receptor stimulation is overcome by the noxious effect of A~2B~ receptors activation ([@B26]) as already suggested for A~2A~ adenosine receptors ([@B65]). Further mechanistic studies suggest that the A~2A~ receptor, when stimulated, facilitates A~2B~ receptor externalization from the endoplasmic reticulum to the plasma membrane, possibly increasing the formation of the A~2A~--A~2B~ dimer ([@B54]). All these results taken together may explain the deleterious activity of adenosine A~2B~ receptor stimulation during an ischemic insult, and the protective effect of A~2B~ receptor antagonists in this condition. Finally, observation that the A~2B~ receptor antagonists did not protect CA1 neurons from neurodegeneration induced by direct glutamate application, confirms that the mechanism underlying their protection against ischemia-induced neurodegeneration is exerted at adenosine receptors that, by the abovementioned mechanisms, regulate extracellular glutamate release. Alternatively, since OGD is above all a problem of efficient energy recovery, the demonstration that A~2B~ receptors control astrocytic and neuronal glycogen metabolism ([@B49]; [@B1]) and glucose utilization by hippocampal slices ([@B46]) may suggest an additional effect of these receptors on metabolic activity during OGD.

Severe OGD increased apoptosis and damaged CA1 pyramidal neurons at 1 and 3 h after the end of the ischemic insult. Immunohistochemistry showed that CA1 pyramidal neurons had significant morphological changes, with increased density of nuclei (HDN neurons), karyorrhexis (LDN neurons) and possibly nuclear fragmentation, as evidenced by the significantly higher number of LDN neurons and cell death after OGD. These results are in agreement with those found by [@B75] in the cerebral cortex of the rat after mild ischemia. Pyknosis is typical of apoptotic cells ([@B17]) and may precede karyorrhexis. We demonstrated that LDN neurons, being highly positive for CytC, were undergoing apoptosis. It has been demonstrated that CytC released into the cytosol binds to apoptotic protease activating factor-1, which leads to activation of caspase-9 which is important in neuronal cell death following ischemia ([@B33]; [@B77]; [@B48]; [@B30]; [@B69]; [@B39], [@B38], [@B40],[@B41]; [@B51]). In turn, caspase-9 is activated by high glutamate levels, as occurs during ischemia ([@B47]). As reported in the literature, activation of mTOR, which has multiple roles in cells among which local protein synthesis at the dendritic and spine level ([@B24]; [@B73]; [@B71]), can be modified in ischemic conditions ([@B14]; [@B42]). As already reported ([@B25]; [@B50]), the decrease of mTOR activation may be secondary to the excitotoxic mechanisms evoked by massive increase of glutamate during OGD, which is known to be an important component of neuronal injury *in vitro* ([@B55]). The participation of decreased mTOR activation in OGD-induced neuronal damage is supported by our results showing decreased activation of mTOR both in the cell body and dendrites of CA1 neurons 3 h after the end of OGD.

Within the limits of the *in vitro* model and the alteration of the neurovascular unit and of neuro glia interplay, we found interesting effects on astrocytic responses. Indeed, astrocytes proliferation, possibly caused, among other stimuli, by increased release of glutamate, is one of the early events that takes place after acute focal CNS damage ([@B5]). In accordance to our previous results ([@B65]), we found evidence of significant, although limited, astrocytic proliferation in CA1 stratum radiatum already 3 h after the end of OGD, possibly caused by increased glutamate release. A~2B~ receptor antagonism significantly prevented all the above neuronal and astrocytic modifications, sparing neurons from the degenerative effects caused by the simil-ischemic conditions, and reducing astrocytes proliferation. CA1 pyramidal neurons treated with the A~2B~ receptor antagonists had a similar morphology to those of control slices, had neither increased nor decreased nuclear density, did not undergo apoptosis, and had activated mTOR levels similar to those of controls.

The similar effects obtained using two different A~2B~ receptor antagonists strengthen the hypothesis that the A~2B~ receptor is involved in the mechanisms of cerebral ischemia. Nevertheless, MRS1754 seems to have lower efficiency than PSB603 on some of the parameters investigated. It is possible that the two drugs act with a different time-course or that PSB603 is more efficacious than MRS1754 in this model.

In summary, our data demonstrate that antagonists of adenosine A~2B~ receptors protect the CA1 area of the hippocampus from an acute damage induced by severe hypoxic/ischemic conditions. The mechanism likely resides in protection from the acute increase of glutamate extracellular concentrations and consequent excitotoxicity. It is worth noticing that since A~2B~ receptors have low affinity for the endogenous ligand adenosine, they are activated only at high extracellular adenosine concentrations that can be reached under pathological conditions such as ischemia, thus representing a selective target ([@B61]).
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